Investing.comDoubao · 实盘不做把握 7/10不做原因:无增量信息
北京时间·🕒 发布 19:36:31·⟳ 抓取 19:38:33 +2m02s·⚡ 决策 10-26 19:50:08 +11m35s·1.3 天前
TransCode在ESMO 2026公布TTX-MC138一期1a数据：安全性达标无DLT，但疗效数据9月底已披露
本次ESMO墙报的核心疗效信息（疾病稳定、延长治疗持续时间、累计98剂）公司已于2026-09-28通过IR新闻稿披露、10-19又预告了本次墙报，今天只是会议embargo解除后的二次呈现，新增的仅是安全性/PK的常规确认；叠加RNAZ极低流动性、约11%买卖价差和持续下行趋势，缺乏可交易edge。
📄 原文Investing.com↗ 原文
TransCode presents phase 1a trial data for cancer therapy
BOSTON - TransCode Therapeutics Inc. (NASDAQ:RNAZ) released results from its Phase 1a clinical trial of TTX-MC138 at th…
不做 TransCode Therapeutics Inc.（RNAZ.US）
无新增事实：一期1a疗效随访9月28日已由公司披露、10月19日预告墙报，今日仅安全性达标+旧疗效数据二次呈现，盘前0%反应；且3000万美元微盘、日均成交不足10万美元、买卖价差约11%、长期阴跌，无可执行正edge。
展开详情(成交明细 / 研究档案 / 原文全文 / 决策记录链)
研究档案
结论摘要
TTX-MC138一期1a安全性达标、无DLT方向偏正面，但疾病稳定/PFS延长等疗效内容9月28日已公开，本次ESMO墙报无新增阳性数据；RNAZ为3000万美元微盘、盘前零反应、价差大且长期阴跌，不构成可交易催化。
消息传播链
- 节点
关键理由
- 一期1a主要安全性终点达标且无DLT属临床推进的必要非充分条件，主力药物已进入二期2a，安全性本身无超预期信息
- 本次墙报核心疗效随访数据在2026-09-28公司新闻稿中已披露，会议呈现为旧数据二次传播
主要风险
- 微盘生物科技股易受小盘情绪/散户炒作驱动出现与基本面无关的剧烈波动，方向不可凭数据增量预测
- 盘前成交量极小、bid/ask价差约11%，任何方向性仓位都面临严重执行与冲击成本风险
反向证据
- 做多前查反向 · 来源 web · 影响 weakens
公司为持续亏损临床期微盘（PE为负），股价13周指数化轨迹100→23、距52周高点约-89%，长期下行且盘前价差约11%，做多缺乏承接与催化
检索:TransCode RNAZ 近期利空 现金 增发 退市 反向拆分 原文 ↗
先例如何影响了这次决策
对本次决策的影响:未改变结论：AVOID基于增量缺失与不可执行性，而非先例胜率
方向:无可对照对齐先例；且结论不依赖涨幅基准，而由数据无增量与流动性决定
涨幅量级:不足以校准幅度，但本事件不进入交易，无需据此设定tp/sl
形态:未做系统先例统计
工具执行结果 · 成功 4 · 降级 1 · 失败 0 · 取消 0
- search_processed_events 成功 stock_tools HTTP · 286 ms
{"result": "search_processed_events:agent query=`rnaz microrna-10b phase 1a trial results disease stabilization | transcode esmo madrid poster ttx-mc138 | transcode therapeutics ttx-mc138 phase 1a esmo 2026 data`；结构化索引覆盖完整 72 小时；旧记录兼容扫描近 69.6/72 小时、2885 条本臂决策(完整)，返回 0 条候选。未命中只表示这些 agent query 表达式没有召 - stock_quote 降级 stock_tools HTTP · 800 ms
{ - fetch_decision_experience 成功 stock_tools_inprocess · 3 ms
{ - web_search 成功 doubao_search · 1,784 ms
豆包搜索结果（原始查询:TransCode Therapeutics TTX-MC138 phase 1a results topline previously announced 2026；API SearchType:web） - web_search 成功 doubao_search · 1,465 ms
豆包搜索结果（原始查询:RNAZ TransCode ESMO 2026 TTX-MC138 poster phase 1a data reaction；API SearchType:web）
原文全文
展开原文 · 1,747 字
BOSTON - TransCode Therapeutics Inc. (NASDAQ:RNAZ) released results from its Phase 1a clinical trial of TTX-MC138 at the European Society for Medical Oncology Congress 2026 in Madrid, Spain, according to a press release statement issued today.
The multicenter, open-label study evaluated safety, tolerability, pharmacokinetic properties and antitumor activity in patients with previously treated advanced solid tumors. TTX-MC138 was administered once every 28 days across four dose levels ranging from 0.8 mg/kg to 4.8 mg/kg.
The study met its primary safety endpoint with no dose-limiting toxicities observed. Dose-dependent plasma exposure was observed across the four evaluated dose levels.
The poster presentation included findings on disease stabilization in the patient population and extended progression-free intervals in a subset of patients. The study also examined exploratory biomarkers related to antitumor immune activity.
"These data provide additional insight into the safety, clinical activity and durability findings observed in the Phase 1a study," said Dan Vlock, TransCode consulting Senior Medical Advisor.
TransCode is a clinical-stage company developing immuno-oncology and RNA-based therapeutics for high-risk and advanced cancers. The company’s lead therapeutic candidate, TTX-MC138, targets metastatic tumors that overexpress microRNA-10b. The therapy is currently being evaluated in a Phase 2a trial under the PRE-I-SPY program in collaboration with Quantum Leap Healthcare Collaborative.
The poster was under embargo from the conference until today.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.
TransCode presents phase 1a trial data for cancer therapy
The multicenter, open-label study evaluated safety, tolerability, pharmacokinetic properties and antitumor activity in patients with previously treated advanced solid tumors. TTX-MC138 was administered once every 28 days across four dose levels ranging from 0.8 mg/kg to 4.8 mg/kg.
The study met its primary safety endpoint with no dose-limiting toxicities observed. Dose-dependent plasma exposure was observed across the four evaluated dose levels.
The poster presentation included findings on disease stabilization in the patient population and extended progression-free intervals in a subset of patients. The study also examined exploratory biomarkers related to antitumor immune activity.
"These data provide additional insight into the safety, clinical activity and durability findings observed in the Phase 1a study," said Dan Vlock, TransCode consulting Senior Medical Advisor.
TransCode is a clinical-stage company developing immuno-oncology and RNA-based therapeutics for high-risk and advanced cancers. The company’s lead therapeutic candidate, TTX-MC138, targets metastatic tumors that overexpress microRNA-10b. The therapy is currently being evaluated in a Phase 2a trial under the PRE-I-SPY program in collaboration with Quantum Leap Healthcare Collaborative.
The poster was under embargo from the conference until today.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.
TransCode presents phase 1a trial data for cancer therapy
决策记录链 · 只追加
每次领取产生一条记录,重新决策追加一条并以 supersedes 指向被替代的记录(ADR 0014)。
b6f0eefd9f· 2026-10-26 19:50 · doubao / doubao-seed-evolving-latest-version · 策略包b7b4acf827b8当前